Pencil Banner Copy AUGUST2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab LEARN MORE HERE

We’re attending ESMO 2023

Visit us at booth 726a

October 20-23, 2023

Madrid, Spain

Stay connected

Spotlight on rivoceranib

Come see the TKI selectivity comparison, the latest rivoceranib data, information on our pipeline, and more.

Learn how the mechanism of action of rivoceranib helps define its clinical potential.

Immersive experience

See the relative selectivity of TKIs through our interactive touchscreen display.


Review our latest data

Visit the poster presentation

Sunday, October 22 | 12:00-13:00 | Hall 8 644P

Abstract Title: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Rivoceranib plus Trifluridine/Tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer

See the phase 3 study results published in The Lancet

At ESMO 2022, we presented our proffered paper on the phase 3 study results comparing rivoceranib in combination with camrelizumab vs sorafenib as a first-line therapy for unresectable hepatocellular carcinoma (uHCC). Look how far we’ve come!

See the phase 3 study results published recently in The Lancet showing a statistically significant and clinically meaningful benefit in progression-free survival and overall survival.

Read the complete article

Explore the Past. Experience the Present. Map the Future.

Explore the Past.
Experience the Present.
Map the Future.


Enjoy and explore

Stop by booth 726a for a latte and explore the past, present, and future of treatment for unresectable hepatocellular carcinoma (uHCC).

Stay connected

Sign up to receive important information about rivoceranib, company news and updates, or to connect with a member of our team.

Look for us at future events